Bookmark and Share

$PCSA Featured in Research Report

Processa Pharmaceuticals (NASDAQ: PCSA), a clinical-stage biopharmaceutical company developing products to improve the survival and/or quality of life for patients who have unmet medical needs, was featured in a research report by Encode Ideas L.P., a health care focused research firm. The full research publication is available at The report reads, “Processa’s pipeline is constructed of development-stage assets that have substantial legacy human data, where the company believes a new approach (dosing, indication, trial design, etc.) can unlock latent value. Processa’s management (David Young, Questcor) and board (Khalid Islam, Gentium and Fennec) have a history of successful drug reclamation projects. The company’s lead asset, eniluracil or PCS6422, was a GSK drug that has been studied in over 1,500 cancer patients, where Processa believes slight changes to the dosing regimen and study design can address previous shortcomings. The other pipeline product of note, PCS499, comes from Concert Pharmaceuticals, where it was studied in Ph2 for diabetic nephropathy, but Processa believes it is better suited for a rare dermatology indication, Necrobiosis Lipoidica (‘NL’). We are enthusiastic about both assets, in particular PCS6422, and feel if there is latent value in either or both, this is the team that can unearth it.”

To view the full press release, visit:

About Processa Pharmaceuticals Inc.

The mission of Processa is to develop products with existing clinical evidence of efficacy for patients with unmet or underserved medical conditions who need treatment options that improve survival and/or quality of life. The company used these criteria for selection to further develop its pipeline programs to achieve high-value milestones effectively and efficiently. Active pipeline programs include: PCS6422 (metastatic colorectal cancer and breast cancer), PCS499 (ulcerative necrobiosis lipoidica) and PCS12852 (GI motility/gastroparesis). The members of the Processa development team have been involved with more than 30 drug approvals by the FDA (including drug products targeted to orphan disease conditions) and more than 100 FDA meetings throughout their careers. For more information, visit the company’s website at

NOTE TO INVESTORS: The latest news and updates relating to PCSA are available in the company’s newsroom at

About BioMedWire

BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published:

BioMedWire (BMW)
San Francisco, California
415.949.5050 Office

BioMedWire is part of the InvestorBrandNetwork.

Monday, February 22nd, 2021 Uncategorized